Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD137 in cancer therapy - bench to bedside.

Immunotherapy·2026
Same author

Special Issue "Novel Therapeutic Targets in Cancers: 3rd Edition".

International journal of molecular sciences·2026
Same author

Special Issue "Molecular Perspectives in Lung Diseases: Pathogenesis, Diagnosis, and Treatment".

International journal of molecular sciences·2026
Same author

A spatiotemporal dependency-aware lightweight CNN-ViT network for 3D MRF with a balanced acceleration strategy.

Medical image analysis·2026
Same author

Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLC.

Cell death & disease·2026
Same author

Multidisciplinary clinics in cancer-models, metrics, and meaning: a review.

The oncologist·2026

Related Experiment Video

Updated: Mar 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Akash Patnaik1,2,3,4, Kenneth D Swanson5, Eva Csizmadia6

  • 1Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Dana Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts. apatnaik1@uchicago.edu.

Cancer Discovery
|March 10, 2017
PubMed
Summary

Cabozantinib, a tyrosine kinase inhibitor, triggers a neutrophil-mediated immune response that eradicates invasive prostate cancer. This discovery highlights a novel mechanism for activating innate immunity against tumors.

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.2K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.0K

Related Experiment Videos

Last Updated: Mar 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.2K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.0K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Kinase inhibitors are used in cancer therapy, but their effects on the tumor immune microenvironment are not well understood.
  • Cabozantinib is a tyrosine kinase inhibitor that has shown promising responses in clinical trials across various cancers.
  • The precise mechanisms by which cabozantinib exerts its antitumor effects, particularly regarding immune system activation, require further investigation.

Purpose of the Study:

  • To investigate the impact of cabozantinib on the tumor immune microenvironment.
  • To elucidate the mechanisms underlying cabozantinib's efficacy in preclinical cancer models.
  • To determine if cabozantinib can activate innate immune responses against cancer cells.

Main Methods:

  • Utilized PTEN/p53-deficient murine prostate cancer models.
  • Administered cabozantinib and assessed tumor eradication.
  • Analyzed the release of neutrophil chemotactic factors (CXCL12, HMGB1) from tumor cells.
  • Investigated the role of neutrophils in tumor clearance using antibody-mediated granulocyte depletion and CXCR4 inhibition (plerixafor).

Main Results:

  • Cabozantinib rapidly eradicated invasive, poorly differentiated PTEN/p53-deficient murine prostate cancer.
  • Tumor eradication was associated with increased release of CXCL12 and HMGB1, leading to neutrophil infiltration.
  • Depletion of neutrophils, HMGB1 neutralization, or blockade of neutrophil chemotaxis abrogated cabozantinib's tumor-clearing effects.

Conclusions:

  • Cabozantinib activates a neutrophil-mediated innate immune response against invasive prostate cancer.
  • The study demonstrates a novel mechanism where a tyrosine kinase inhibitor enhances antitumor immunity via neutrophils.
  • These findings suggest potential therapeutic strategies combining kinase inhibitors with immunomodulatory approaches for cancer treatment.